Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Vision for Digital Health Transformation


Foreword by the Minister of Health

In the following pages, we reveal a compelling vision for the future of digital health in Lebanon—an innovative blueprint developed through collaborative, forward-thinking, and inclusive efforts. With the recognition of digital technology as an integral driver of healthcare improvement, the Ministry of Public Health (MoPH) has been at the forefront, rallying essential stakeholders and orchestrating strategic discussions aimed at redefining our healthcare landscape.

This grand vision is grounded in the National Health Strategy, launched by the MoPH in January 2023. Recognizing the importance of digital health transformation, this strategy identified it as a crucial pillar. From this sturdy foundation, the Digital Health Retreat was organized on May 18, 2023. This retreat acted as a catalyst, creating an arena for stakeholders to identify the challenges and opportunities present in Lebanon's digital health ecosystem. A consensus was reached, emphasizing the pressing need for a consolidated vision that enables our healthcare system and augments health outcomes for our people.

Our healthcare sector, while resilient, faces its fair share of hurdles. With this understanding, and building upon the significant investments in digital health stipulated by the National Health Strategy, our vision aims to utilize digital solutions to overcome these barriers, thereby enriching healthcare outcomes. This is a vision of synergy, empowerment, and readiness for the evolving landscape of healthcare.

Our transformative vision transcends policy constraints. It establishes a detailed blueprint for developing a resilient digital health infrastructure. These strategies encompass a multitude of aspects—from digital platforms and mobile applications to health information exchange systems and more.
The implications of this digital health transformation are immense. From improved care coordination to enhanced population health outcomes, this vision for digital health, inherent in the National Health Strategy, is poised to serve as a guiding beacon for our future. Our journey begins here, and we invite you to join us as we map the pathway for a healthier Lebanon. Together, we can transform this vision into reality.

Vision for Digital Health Transformation
    5
ATC Name B/G Ingredients Dosage Form Price
N05AX15 REAGILA G Cariprazine HCl - 3mg 3mg Capsule, hard 6,394,003 L.L
A02BC01 RISEK G Omeprazole - 20mg 20mg Capsule, enteric coated 302,365 L.L
N05AX15 REAGILA G Cariprazine HCl - 4.5mg 4.5mg Capsule, hard 6,394,003 L.L
N05AX15 REAGILA G Cariprazine - 6mg 6mg Capsule, hard 6,394,003 L.L
N01AH06 REMIFENTANIL MEDIS G Remifentanil (HCl) - 1mg 1mg Injectable powder 1,101,951 L.L
N01AH06 REMIFENTANIL MEDIS G Remifentanil (HCl) - 5mg 5mg Injectable powder 2,576,146 L.L
P01AB01 RAMAZOL G Metronidazole - 500mg 500mg Tablet 216,359 L.L
A02BC01 RISEK G Omeprazole - 40mg 40mg Capsule, enteric coated 522,755 L.L
G04BE08 RAVANA G Tadalafil - 20mg 20mg Tablet 500,421 L.L
V03AB35 RELANCIUM G Sugammadex - 100mg/ml 100mg/ml Injectable solution 45,660,028 L.L
A10BX02 REPAGLINIDE ARROW LAB G Repaglinide - 2mg 2mg Tablet 831,839 L.L
A10BX02 REPAGLINIDE ARROW LAB G Repaglinide - 0.5mg 0.5mg Tablet 831,839 L.L
M01AB05 RAPIDUS G Diclofenac potassium - 50mg 50mg Tablet, coated 287,582 L.L
A02BC01 RISEK G Omeprazole (sodium) - 40mg 40mg Injectable lyophilised powder for solution 592,635 L.L
A10BX02 REPAGLINIDE ARROW LAB G Repaglinide - 1mg 1mg Tablet 831,839 L.L
D10AD01 RETACNYL - 0.05 % G Tretinoin - 0.05% Cream 584,571 L.L
G04BE08 RAVANA G Tadalafil - 5mg 5mg Tablet 1,501,264 L.L
C10AA07 ROSUCOR G Rosuvastatin (calcium) - 10mg 10mg Tablet, film coated 487,623 L.L
V03AE01 RESICAL G Calcium Polystyrene Sulphonate - 93.5% w/w 93.5% Powder 1,292,776 L.L
A02BC02 RAZON 40 G Pantoprazole (sodium) - 40mg 40mg Tablet, enteric coated 727,019 L.L
C10AA07 ROSUPHAR G Rosuvastatin (calcium) - 10mg 10mg Tablet, film coated 487,623 L.L
V03AE01 RESINCALCIO G Calcium Polystyrene Sulphonate - 99.75g/100g 99.75% w/w Powder for suspension 1,673,084 L.L
A02BC02 RAZON 40 G Pantoprazole (sodium) - 40mg 40mg Tablet, enteric coated 1,252,461 L.L
C10AA07 ROSUVAS G Rosuvastatin (calcium) - 10mg 10mg Tablet, film coated 450,187 L.L
V03AE01 RESINSODIO G Sodium polystyrene sulphonate - 99.75g/100g 99.75g/100g Powder for suspension 1,534,668 L.L
C10AA07 ROVASTIN G Rosuvastatin (calcium) - 10mg 10mg Tablet 560,574 L.L
D10AD51 RETINOMYCIN G Tretinoin - 0.025%, Erythromycin - 4% Gel 662,962 L.L
C10AA07 ROXARDIO G Rosuvastatin (calcium) - 10mg 10mg Tablet, film coated 749,058 L.L
C05AE01 RECTOGESIC G Glyceryl trinitrate - 0.2% w/w 0.2% w/w Ointment 2,553,301 L.L
N01BB09 ROPIVACAINA MOLTENI G Ropivacaine HCl - 75mg/10ml 7.5mg/ml Injectable solution 2,332,911 L.L
    5
Sitemap
© Copyrights reserved to Ministry of Public Health 2025